Lung Cancer

On November 10, 2022, the FDA approved this new immunotherapy, in combination with the PD-L1 inhibitor durvalumab (Imfinzi; AstraZeneca) and platinum-based chemotherapy, for the treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and no EGFR or ALK genomic alterations. Read More ›

On November 8, 2022, the FDA approved a new indication for cemiplimab-rwlc (Libtayo; Regeneron), a PD-1 inhibitor, in combination with platinum-based chemotherapy, for the treatment of adults with advanced NSCLC and no EGFR, ALK, or ROS1 aberrations. Read More ›

The phase 3 CheckMate-816 trial establishes a new standard of care for resectable non–small-cell lung cancer (NSCLC): neoadjuvant nivolumab (Opdivo) plus chemotherapy. Read More ›

Read More ›

The COVID-19 pandemic continues to impact healthcare across the globe. We are yet to see the full effect of the COVID-19 pandemic on patients with cancer, including patients with non–small-cell lung cancer (NSCLC). With the recent emergence of the COVID-19 Omicron variant, we expect this impact on healthcare and cancer care to continue. The Year in Review series is an important tool to reach audiences and provide timely and relevant information on treatment advances in the oncology setting. Read More ›

Multidisciplinary tumor board members work closely to make the best clinical decisions for their patients with cancer to improve patient and institutional outcomes. Their decisions should be based on the clinical data of each patient in line with their own clinical and institutional guidelines. Read More ›

Immunotherapy and targeted therapy have resulted in improved survival rates in patients with NSCLC over the past decade. Read More ›

Sotorasib showed encouraging anticancer activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC. Read More ›

Data from the CodeBreaK 100 NSCLC subset population prompted the FDA to grant sotorasib accelerated approval for patients with KRAS^G12C mutation–positive NSCLC. Read More ›

Finding the right balance between cancer-induced fatigue and immune-oncology–induced fatigue and doing enough exercise to improve general health and better cancer outcomes is a fundamental part of treating patients with cancer. Finding this balance for patients with NSCLC receiving immune-oncology therapy is a key element of overall care for these patients. Read More ›